The overall increase in all the NK cell receptors, and the significant increase in NK cells expressing the heterodimeric C-type lectin receptor CD94 in the recurrence-free patient cohort (RFC), but not in the early recurrence patient cohort (RC), might indicate that activated NK cells are supporting the anti-tumor immune response. The gene discussed is CLEC4D; the disease is neoplasm.